A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02071368 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Canagliflozin, 300 mg
DRUG: Metformin XR, 500 mg
DRUG: CANA/MET XR FDC, Formulation 1, 150 mg/500
DRUG: CANA/MET XR FDC, Formulation 2, 150 mg/500 mg

Sponsor

Janssen Research & Development, LLC